You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 62 No. 6, June 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (9)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Musculoskeletal Syndromes (Chronic Fatigue, Gulf War)
 •Neurology, Other
 •Alert me on articles by topic

Brain {gamma}-Aminobutyric Acid Changes in Stiff-Person Syndrome

Lucien M. Levy, MD, PhD; Igor Levy-Reis, MD; Mavis Fujii, MD; Marinos C. Dalakas, MD

Arch Neurol. 2005;62:970-974.

Background  Patients with stiff-person syndrome (SPS) have circulating antibodies against glutamic acid decarboxylase, the rate-limiting enzyme responsible for the synthesis of {gamma}-aminobutyric acid (GABA). Although the patients’ symptoms of stiffness and unexpected spasms can be explained on the basis of reduced or impaired inhibitory neurotransmitters, such as GABA, it is unclear whether the level of GABA in the brains of these patients is reduced and, if so, whether the reduction is due to anti–glutamic acid decarboxylase antibodies.

Objective  To measure GABA levels in the brains of patients with SPS.

Design  Prospective case-control study.

Setting  National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Md.

Patients  Eight patients with SPS with high titers of circulating anti–glutamic acid decarboxylase antibodies and typical clinical symptoms of SPS and 16 control subjects.

Main Outcome Measures  Results of brain magnetic resonance imaging and magnetic resonance spectroscopy, which measures GABA levels in specific brain regions.

Results  No abnormalities were noted on brain magnetic resonance images. A prominent and significant decrease in GABA level was, however, observed in the sensorimotor cortex and a smaller decrease in the posterior occipital cortex but not in the cingulate cortex or pons.

Conclusions  The reduction of brain GABA in patients with SPS supports the clinical symptoms and indicates that the inhibitory GABAergic pathways are involved in the disease. Regardless of the responsible autoantigens, in SPS autoantibodies block the function of GABAergic neurons and interfere with the synthesis of GABA but do not cause structural changes in the brain.


Author Affiliations: Neuroimaging Branch (Drs Levy and Levy-Reis) and Neuromuscular Diseases Section (Drs Fujii and Dalakas), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Md; and Neuroradiology Section, George Washington University Medical Center, Washington, DC (Drs Levy and Levy-Reis).



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome
Raju et al.
Brain 2006;129:3270-3276.
ABSTRACT | FULL TEXT  

Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies.
Rakocevic et al.
Neurology 2006;67:1068-1070.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.